2023-10-22T03:31:07+03:00[Europe/Moscow] en true <p>if patients are able to be treated with CCBs</p>, <p>amlodipine, diltiazem, nifedipine </p>, <p>a</p>, <p>b</p>, <p>c</p>, <p>d</p>, <p>none; monitor for disease progression </p>, <p>ambrisentan + tadalafil </p>, <p>ERAs, PDE5 inhibitors, Riociguat </p>, <p>bosentan, macitentan, riociguat, sildenafil </p>, <p>continuous IV epoprostenol; treprostinil; titrate both </p>, <p>continuous IV epoprostenol </p>, <p>inhaled prostacyclin, oral ERA antagonist, PDE-5 inhibitor, Riociguat </p>, <p>lung transplant; palliative care (if patient is not a candidate) </p>, <p>thrombocytopenia </p>, <p>a</p>, <p>b</p>, <p>c,d </p>, <p>cyclosporine, glyburide, pregnancy </p>, <p>negative pregnancy test monthly </p>, <p>pregnancy </p>, <p>pregnancy, idiothetic pulmonary fibrosis </p>, <p>c</p>, <p>b</p>, <p>drop in mAP &gt;=10 mmHg; absolute mAP of &lt;40mmHg</p>, <p>riociguat, ERAs</p> flashcards
PAH & PF Therapeutics

PAH & PF Therapeutics

  • if patients are able to be treated with CCBs

    What does the Acute Vasoreactivity test tell us?

  • amlodipine, diltiazem, nifedipine

    What are the CCBs of choice in PAH? (3)

  • a

    No symptoms with exercise or at rest.

    a) Class I

    b) Class II

    c) Class III

    d) Class IV

  • b

    No symptoms at rest; SOB with normal activity.

    a) Class I

    b) Class II

    c) Class III

    d) Class IV

  • c

    May or may not have symptoms at rest; SOB, and fatigue limit normal

    activities.

    a) Class I

    b) Class II

    c) Class III

    d) Class IV

  • d

    Symptoms at rest and severe symptoms with any activity.

    a) Class I

    b) Class II

    c) Class III

    d) Class IV

  • none; monitor for disease progression

    What is the treatment for WHO FC I?

  • ambrisentan + tadalafil

    What is the combo therapy for treatment-naive patients?

  • ERAs, PDE5 inhibitors, Riociguat

    What are the treatment options for WHO FC III-treatment naive who can't

    tolerate combo therapy? (3)

  • bosentan, macitentan, riociguat, sildenafil

    What are the treatment options for WHO FC II who can't tolerate combo therapy? (4)

  • continuous IV epoprostenol; treprostinil; titrate both

    What are the treatment options for WHO FC III-Rapid disease progression? (2)

  • continuous IV epoprostenol

    What is the 1st line therapy for WHO FC IV patients?

  • inhaled prostacyclin, oral ERA antagonist, PDE-5 inhibitor, Riociguat

    What are the treatment options for WHO FC IV patients who can't tolerate

    the 1st line option? (4)

  • lung transplant; palliative care (if patient is not a candidate)

    If inadequate response to maximal therapy, what are the treatments? (2)

  • thrombocytopenia

    The prostacyclin analogs have a class effect of ____________.

  • a

    Which is contraindicated in hepatic impairment when taken orally?

    a) treprostinil

    b) epoprostenol

    c) illoprost

    d) selexipag

  • b

    Which is contraindicated in HFrEF + decreased LV EF?

    a) treprostinil

    b) epoprostenol

    c) illoprost

    d) selexipag

  • c,d

    Which have no contraindications?

    a) treprostinil

    b) epoprostenol

    c) illoprost

    d) selexipag

  • cyclosporine, glyburide, pregnancy

    Bosentan Contraindications? (3)

  • negative pregnancy test monthly

    What do the ERA require before prescribing?

  • pregnancy

    Who are the ERAs contraindicated in?

  • pregnancy, idiothetic pulmonary fibrosis

    Ambrisentan CIs? (2)

  • c

    Which has to be taken with food?

    a) ERA

    b) PDE-5 inhibitors

    c) Nintedanib

    d) Pirfenidone

  • b

    Which can cause hearing loss?

    a) ERA

    b) PDE-5 inhibitors

    c) Nintedanib

    d) Pirfenidone

  • drop in mAP >=10 mmHg; absolute mAP of <40mmHg

    What confirms a positive Vasoreactivity test? (2)

  • riociguat, ERAs

    Which drugs require REMS? (2)